News Review: DryShips, Inc. (NASDAQ:DRYS), PharmAthene, Inc. (NYSEMKT:PIP)

DryShips, Inc. (NASDAQ:DRYS)

The company announced its last quarter financial performance results on 11/09/2016. DryShips, Inc. (NASDAQ:DRYS) belongs to Transportation sector that surged 34.21% in value when last trading session closed at $5.61. The company has a market capitalization of $75.68 Million. The company’s stock has a Return on Assets (ROA) of -210.9 percent, a Return on Equity (ROE) of 0 percent and Return on Investment (ROI) of -271.1 percent. The company reached its 52-Week high of $2227.2 on Apr 28, 2016 and 52-Week low of $1.97 on Jan 27, 2017.

Earnings per share (ttm) for DryShips, Inc. (NASDAQ:DRYS) according to Finviz Data is $-219.46.

This company was Upgrade by Imperial Capital on 28-Oct-14  to Outperform.

There is no forecast data available.

Financial History:

Following Earnings result, share price were DOWN 16 times out of last 27 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 16% percent of times. It has met expectations  0 times and missed earnings  5  times.

Company Profile:

Dryships Inc., based in Greece, is an owner and operator of drybulk carriers that operate worldwide.

PharmAthene, Inc. (NYSEMKT:PIP):

PharmAthene, Inc. (NYSEMKT:PIP) belongs to Medical sector closed its last session with a loss of -69.39 percent and closed its previous trading session at $1.01. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $1.75. The company has the Market capitalization of $64.34 Million. The company’s stock has a Return on Assets (ROA) of 221.8 percent, a Return on Equity (ROE) of 238.1 percent and Return on Investment (ROI) of -20.9 percent. The company reached its 52-Week high of $3.5 on Jan 19, 2017 and 52-Week low of $0.47 on Feb 6, 2017.

This company was Initiated by Aegis Capital on 6-Mar-13 to Buy.

The 1 analysts offering 12-month price forecasts for PharmAthene Inc have a median target of 6.00, with a high estimate of 6.00 and a low estimate of 6.00. The median estimate represents a +494.06% increase from the last price of 1.01.

Financial History:

Following Earnings result, share price were UP 3 times out of last 3 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 0% percent of times. It has met expectations  0 times and missed earnings  4  times.

Revenue is expected to range from 13.5 Million to 13.5 Million with an average of 13.5 Million.

Company Profile:

PharmAthene Inc. is a biodefense company formed to meet the critical needs of the United States by developing biodefense products. PharmAthene is dedicated to the rapid development of important and novel biotherapeutics to address biological pathogens and chemicals that may be used as weapons of bioterror. PharmAthene’s lead programs include Valortim and Protexia.